 Home > Medical News > Latest Medical News > Baiyunshan: Cefixime capsules passed the consistency evaluation of generic drugs

Baiyunshan: Cefixime capsules passed the consistency evaluation of generic drugs

 Last Update: 2021-06-22
 Source: Internet
 Author: User

Tags

1 3 dimeth

2 3 picture

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 4, Guangzhou Baiyunshan Pharmaceutical Group stated that its subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co.
, Ltd.
Baiyunshan Pharmaceutical General Factory received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, cefixime capsules The quality and efficacy consistency evaluation of generic drugs has been passed
.

Cefixime is a third-generation cephalosporin antibiotic.
This product is suitable for Streptococcus (except Enterococcus) that are sensitive to cefixime, pneumococcus, Neisseria gonorrhoeae, Branhamococcus catarrhalis, Escherichia coli, Cree.
The following bacterial infectious diseases caused by Burrella, Serratia, Proteus, and Influenza bacteria: 1.
Bronchitis, bronchiectasis (when infected), secondary infections of chronic respiratory infections, pneumonia; 2 .
Pyelonephritis, cystitis, gonococcal urethritis; 3.
Cholecystitis, cholangitis; 4.
Scarlet fever; 5.
Otitis media, paranasal sinusitis
.

At present, domestic manufacturers of cefixime capsules also include CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Jinri Pharmaceutical (China) Co.
, Ltd.
, Qilu Pharmaceutical Co.
, Ltd.
, Chengdu Better Pharmaceutical Co.
, Ltd.
, and Tianjin Pharmaceutical Group Jinkang Pharmaceutical Co.
, Ltd.
Limited
.

According to data from Meinenet, the sales of cefixime capsules in public hospitals and urban retail pharmacies in China in 2020 will be RMB 506.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.